Innoviva, Inc.

DB:HVE Stock Report

Market Cap: €1.1b

Innoviva Past Earnings Performance

Past criteria checks 3/6

Innoviva's earnings have been declining at an average annual rate of -12.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 1.8% per year. Innoviva's return on equity is 9.7%, and it has net margins of 18.3%.

Key information

-12.5%

Earnings growth rate

-1.5%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate1.8%
Return on equity9.7%
Net Margin18.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Innoviva makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:HVE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2435365111-21
30 Jun 243301451130
31 Mar 243121811090
31 Dec 23310180980
30 Sep 23290508431
30 Jun 23290233830
31 Mar 23318233710
31 Dec 22331214580
30 Sep 22373293460
30 Jun 2240499210
31 Mar 22396188130
31 Dec 21392266160
30 Sep 21375309170
30 Jun 21365265170
31 Mar 21344253160
31 Dec 20337224120
30 Sep 2032221680
30 Jun 2029922890
31 Mar 20285189110
31 Dec 19261157150
30 Sep 19265375170
30 Jun 19261382130
31 Mar 19264399130
31 Dec 18261395190
30 Sep 18251190170
30 Jun 18238166240
31 Mar 18229147300
31 Dec 17217134320
30 Sep 17191101350
30 Jun 1717692320
31 Mar 1715072280
31 Dec 1613460230
30 Sep 1611338220
30 Jun 169319220
31 Mar 1671-4210
31 Dec 1554-19200
30 Sep 1538-39210
30 Jun 1526-56250
31 Mar 1516-68290
31 Dec 148-74350
30 Sep 143-66350
30 Jun 142-55320
31 Mar 142-9270

Quality Earnings: HVE has a large one-off loss of $98.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: HVE's current net profit margins (18.3%) are higher than last year (17.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HVE's earnings have declined by 12.5% per year over the past 5 years.

Accelerating Growth: HVE's earnings growth over the past year (29.5%) exceeds its 5-year average (-12.5% per year).

Earnings vs Industry: HVE earnings growth over the past year (29.5%) exceeded the Pharmaceuticals industry 25.4%.

Return on Equity

High ROE: HVE's Return on Equity (9.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 12:32
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Innoviva, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jon LangenfeldBaird
James BirchenoughBarclays
Patrick TrucchioBerenberg